In our study, we used a panel of PCa cell lines, including LNCaP (androgen-responsive metastatic EA PCa), C4-2B (CRPC developed from parental LNCaP) and 22Rv1 (Enz-resistant CRPC), and MDA PCa 2b (androgen-independent AA PCa) to study the functional impacts of miR-99b-5p/mTOR/AR/SMARCD1 signaling axis in PCa aggressiveness and drug resistance in EA and AA PCa. The gene discussed is MTOR; the disease is posterior cortical atrophy.